Phastar is building up its data science group as AI and machine learning ‘are rapidly modernizing clinical trials’ and Synteract boosts its centers of development in oncology and rare/orphan diseases, among other people on the move this month.
SGS’ OneVision initiative is working to standardize record-keeping across the global life sciences industry in an aim to accelerate laboratory testing, development, and eliminate paper-based systems.
Improving the prognostic value of early phase data is among one of several ways to increase the probability of successes in drug development, a process which has become more expensive as failure rates have risen, says an industry expert.
SGS’ completed the ₤8.7m expansion of its large molecule testing facility in Glasgow and made room to increase its existing biosafety service and PCR platform capabilities.
SGS has expanded its Chennai, India-based laboratory with the addition of inductively coupled plasma mass spectrometry systems to address updated ICH Q3D regulatory guidelines.
The biopharmaceutical analytical and bioanalytical contract solutions provider SGS is investing more than $1.7m to expand its North American biopharmaceutical testing capabilities.
The contract services provider is now collecting and using peripheral blood mononuclear cells (PBMCs) for early phase clinical trials at its Antwerp, Belgium-based Clinical Pharmacology Unit (CPU).
